TNFRSF17 and AL amyloidosis: Despite evidence suggesting that BCMA expression is lower in plasma cells derived from AL amyloidosis compared to MM [50,52], this did not appear to negatively impact the therapeutic efficacy of BCMA-targeted CAR-T therapy.